Table 4 The most severe and highest risk potential DDIs that were identified
Potential DDI | Potential Duration of concomitant therapy | Risk category | Severity | Potential adverse effects |
|---|---|---|---|---|
Doxycycline + Isotretinoin | 14 days | X | Major | Intracranial hypertension |
Domperidone + Clarithromycin | 7 days | X | Major | QTc- prolongation, sudden cardiac death |
Celecoxib + Ibuprofen | 3 days | X | Major | Gastrointestinal ulceration and bleeding |
Spironolactone + Potassium Chloride supplements | 7 days | X | Major | Severe hyperkalemia |
Rivaroxaban + Aceclofenac | 5 days | D | Major | Excessive/Uncontrolled bleeding |
Morphine + Pregabalin | 30 days | D | Major | Slowed or difficult breathing, Respiratory depression |
Tramadol + Gabapentin | 5 days | D | Major | Slowed or difficult breathing, Respiratory depression |
Dolutegravir + Carbamazepine | 60 days | D | Major | Treatment failure due to diminished efficacy of Dolutegravir |
Haloperidol + Chlorpromazine | 30 days | D | Major | Arrhythmias, Torsades de Pointes |
Morphine + Chlorpheniramine | 5 days | D | Major | Slowed or difficult breathing, Respiratory depression |